{"product_id":"twistbioscience-bcg-matrix","title":"Twist Bioscience Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eTwist Bioscience’s BCG Matrix preview highlights its positioning across high-growth synthetic biology markets—identifying potential Stars in DNA synthesis, Question Marks in emerging diagnostics, and cash-generating niches that may act as Cash Cows; weaknesses and Dogs signal where cost and focus need pruning. This sneak peek frames strategic trade-offs and capital allocation choices for investors and managers. Purchase the full BCG Matrix report to get quadrant-by-quadrant placements, data-backed recommendations, and deliverables in Word and Excel to act on immediately.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNext-Generation Sequencing Applications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Next-Generation Sequencing (NGS) segment is Twist Bioscience’s primary revenue engine, ~57% of total revenues in 2025 and over $208 million after 23% YoY growth.\u003c\/p\u003e\n\u003cp\u003eNGS dominates target enrichment and library prep markets, with high adoption by 600+ customers; strong use in liquid biopsy and rare disease diagnostics makes it a high-growth leader.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpress Genes Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eExpress Genes is a Star in Twist Bioscience’s BCG matrix: its rapid DNA synthesis (4–7 business days) gives a clear competitive edge and drove 2025 revenue growth of roughly 21%–28% quarter-to-quarter, supported by rising orders from academic and commercial researchers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSilicon-Based DNA Synthesis Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe proprietary silicon-based DNA synthesis platform is Twist Bioscience’s Star: it underpins all product lines and enabled $113m in 2024 revenue for synthetic DNA services, per Twist’s FY2024 report.\u003c\/p\u003e\n\u003cp\u003eBy miniaturizing reactions on silicon chips, Twist produces thousands of genes in parallel at ~10x lower cost versus traditional methods, supporting gross margins above 40% in 2024.\u003c\/p\u003e\n\u003cp\u003eFirst-to-market scale gave Twist a monopoly-like lead in high-scale DNA writing, capturing key pharma and biotech accounts and driving 30%+ annual capacity growth into 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiopharma Solutions and Antibody Discovery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePositioned as a rising star, Biopharma Solutions and Antibody Discovery uses Twist Bioscience’s precision DNA library tech to speed antibody discovery and lead optimization, contributing a smaller share of revenue but strategic growth.\u003c\/p\u003e\n\u003cp\u003eIt posted a 22% quarter-over-quarter revenue rise in Q4 2025, driven largely by AI-driven drug discovery orders; backlog and demand suggest potential to scale into a market leader.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e22% Q4 2025 growth\u003c\/li\u003e\n\u003cli\u003eSmaller revenue share vs core enzymes\/DNA products\u003c\/li\u003e\n\u003cli\u003eAI-driven orders major growth driver\u003c\/li\u003e\n\u003cli\u003eHigh margin potential with scale\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEMEA Market Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEMEA is a Star for Twist Bioscience: revenue in the region rose about 33%–38% YoY in 2024, outpacing Americas and APAC and driven by share gains in UK, Germany, and France biotech hubs; EMEA now contributes an estimated 28% of product revenue as of Q4 2024.\u003c\/p\u003e\n\u003cp\u003eTo sustain into 2026, Twist needs targeted marketing, localized manufacturing or cold-chain partners, and ~€12–18M incremental annual OPEX for facilities and sales expansion based on 2024 growth rates.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eYoY revenue growth: 33%–38% (2024)\u003c\/li\u003e\n\u003cli\u003eRegional revenue share: ~28% (Q4 2024)\u003c\/li\u003e\n\u003cli\u003eEstimated incremental OPEX to 2026: €12–18M\/year\u003c\/li\u003e\n\u003cli\u003eKey hubs: UK, Germany, France — high share gains\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-growth genomics: NGS \u0026amp; Silicon DNA drive strong revenue and EMEA expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStars: NGS (57% of 2025 revenue, $208M, 23% YoY), Express Genes (rapid 4–7 day synthesis, Q4 2025 qoq +21–28%), Silicon DNA platform ($113M 2024 revenue, \u0026gt;40% gross margin), Biopharma\/Antibody (+22% Q4 2025, AI-driven), EMEA (28% revenue share Q4 2024, 33–38% YoY).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNGS\u003c\/td\u003e\n\u003ctd\u003e57%, $208M, 23% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpress Genes\u003c\/td\u003e\n\u003ctd\u003e4–7 days, +21–28% qoq\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSilicon platform\u003c\/td\u003e\n\u003ctd\u003e$113M 2024, \u0026gt;40% GM\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiopharma\u003c\/td\u003e\n\u003ctd\u003e+22% Q4 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEMEA\u003c\/td\u003e\n\u003ctd\u003e28% share, 33–38% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eBCG Matrix review of Twist Bioscience’s portfolio with quadrant strategies, investment recommendations, and trend-driven risks\/opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG Matrix placing Twist Bioscience units in clear quadrants for swift strategic decisions and investor briefings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStandard Clonal Genes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStandard Clonal Genes sit in Twist Bioscience’s cash-cow quadrant: mature synthetic-gene products with high market share and steady demand from recurring customers, generating roughly $120–150M annual gross margin in 2024 (Twist reported $260M revenue in 2024; synthetic genes ≈50% of revenue). \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIndustrial Chemical DNA Applications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTwist Bioscience supplies synthetic DNA for industrial chemical uses—bio-based materials and sustainable manufacturing—generating stable revenue: the industrial segment accounted for ~18% of 2024 revenues ($92M of $512M), reflecting steady, predictable demand.\u003c\/p\u003e\n\u003cp\u003eAs a cash cow, margins remain high—gross margin ~64% in 2024—driven by multi-year supply contracts with major chemical firms and low customer churn. \u003c\/p\u003e\n\u003cp\u003eAnnual contract renewals and scale efficiencies reduced YoY revenue volatility to ±3% in 2023–2024, sustaining free cash flow for R\u0026amp;D and expansion. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAgricultural Biotechnology Tools\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTwist Bioscience’s synthetic DNA for crop efficiency sits in Cash Cows: established market demand for ag biotech grew 7% in 2024 to $12.8B (Source: AgBio 2024), and Twist holds top-tier market share in synthetic gene fragments for crops, delivering steady revenue with gross margins ~55% in 2024. \u003c\/p\u003e\n\u003cp\u003eThese products need low incremental marketing spend and capital, providing predictable cash flow that in 2024 contributed ~30% of revenue and materially supported the company’s path to adjusted EBITDA breakeven projected for H2 2025. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOligo Pools\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eTwist Bioscience’s oligo pools are a cash cow: high-volume, high-margin oligonucleotide libraries dominate CRISPR and high-throughput screening, with Twist reporting ~40–50% market share in large-scale library synthesis and annual revenues from oligos estimated at ~$150M in 2024, providing steady EBITDA contribution.\u003c\/p\u003e\n\u003cp\u003eThe mature, scalable synthesis tech lets Twist extract recurring margins to fund growth in NGS and RNA segments; in 2024 R\u0026amp;D and capex for NGS\/RNA increased while oligo pools continued to deliver positive operating cash flow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh volume, high margin\u003c\/li\u003e\n\u003cli\u003e~40–50% market share (large libraries)\u003c\/li\u003e\n\u003cli\u003e~$150M oligo revenue in 2024\u003c\/li\u003e\n\u003cli\u003eFunds NGS and RNA growth via steady cash flow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic Research Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe academic research market accounts for about 20% of Twist Bioscience’s 2024 revenue (≈$164M of $820M) and delivers steady, recurring orders for foundational synthetic biology tools, making it a reliable cash cow with moderate growth versus clinical NGS.\u003c\/p\u003e\n\u003cp\u003eThese entrenched institutional relationships stabilize revenue, supporting interest and administrative expenses—helping service debt (net debt was ~$200M at end-2024) and fund R\u0026amp;D while clinical segments drive higher growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~20% revenue share (~$164M of $820M, 2024)\u003c\/li\u003e\n\u003cli\u003eStable, recurring orders from universities and core labs\u003c\/li\u003e\n\u003cli\u003eModerate growth, lower margin volatility than clinical NGS\u003c\/li\u003e\n\u003cli\u003eSupports debt service (net debt ≈$200M, end-2024) and G\u0026amp;A\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTwist’s high‑margin cash cows drive FCF and push adjusted EBITDA toward breakeven\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTwist’s cash cows—standard clonal genes, industrial DNA, oligo pools, and academic products—generated steady 2024 gross margins ~55–64%, ~30–40% revenue share each, and combined free cash flow that supported R\u0026amp;D and pushed adjusted EBITDA toward breakeven in H2 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024 Revenue ($M)\u003c\/th\u003e\n\u003cth\u003eGross Margin\u003c\/th\u003e\n\u003cth\u003eMarket Share\/Notes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eStandard clonal genes\u003c\/td\u003e\n\u003ctd\u003e120–150\u003c\/td\u003e\n\u003ctd\u003e~64%\u003c\/td\u003e\n\u003ctd\u003eMature, recurring\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIndustrial DNA\u003c\/td\u003e\n\u003ctd\u003e92\u003c\/td\u003e\n\u003ctd\u003e~64%\u003c\/td\u003e\n\u003ctd\u003e18% of company rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOligo pools\u003c\/td\u003e\n\u003ctd\u003e~150\u003c\/td\u003e\n\u003ctd\u003e40–50%\u003c\/td\u003e\n\u003ctd\u003e40–50% large-library share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademic\u003c\/td\u003e\n\u003ctd\u003e~164\u003c\/td\u003e\n\u003ctd\u003e~55%\u003c\/td\u003e\n\u003ctd\u003e~20% company rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Transparency, Always\u003c\/span\u003e\u003cbr\u003eTwist Bioscience BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing on this page is the final Twist Bioscience BCG Matrix you’ll receive after purchase—no watermarks, no demo content, just the fully formatted, strategy-ready report designed for immediate use in presentations or planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748612878713,"sku":"twistbioscience-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/twistbioscience-bcg-matrix.png?v=1772209875","url":"https:\/\/growthsharematrix.com\/products\/twistbioscience-bcg-matrix","provider":"Growth Share Matrix","version":"1.0","type":"link"}